Heparanase upregulation in high glucose-treated endothelial cells is prevented by insulin and heparin

Experimental Biology and Medicine

Volumn 232, Issue 7, 2007, Pages 927-934

  Han, Juying ^a   Woytowich, Adrienne E ^a   Mandal, Anil K ^b   Hiebert, Linda M ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Endothelial cells; Heparanase; Heparin; High glucose; Insulin

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GLUCOSE; HEPARANASE; HEPARIN; HYDROGEN PEROXIDE; INSULIN; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SULFUR 35;

ANIMAL CELL; AORTA; ARTICLE; CELL LYSATE; CONTROLLED STUDY; CORNEA; CULTURE MEDIUM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GEL FILTRATION; NONHUMAN; OSMOLARITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTILLATION; SWINE; UPREGULATION;

ANIMALS; AORTA; CELLS, CULTURED; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLUCOSE; GLUCURONIDASE; HEPARIN; HYDROGEN PEROXIDE; INSULIN; RNA, MESSENGER; SWINE; UP-REGULATION;

BOVINAE; SUS;

EID: 34347375504     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen JS. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 312:871-874, 1996.
2. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309, 1995.
3. Stehouwer CD, Schaper NC. The pathogenesis of vascular complications of diabetes mellitus: one voice or many? Eur J Clin Invest 26:535-543, 1996.
4. Stehouwer C. von Willebrand factor, dysfunction of the vascular endothelium, and the development of renal and vascular complications in diabetes. In: Mogensen CE, Ed. The Kidney and Hypertension in Diabetes Mellitus (4th ed.). Boston, Kluwer Academic Publishers, pp199-208, 1998.
5. Borsum T. Biochemical properties of vascular endothelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol 60:279-286, 1991.
6. Elliott TG, Cockcroft JR, Groop PH, Viberti GC, Ritter JM. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci (Lond) 85:687-693, 1993.
7. Verma S, Arikawa E, McNeill JH. Long-term endothelin receptor blockade improves cardiovascular function in diabetes. Am J Hypertens 14:679-687, 2001.
8. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233-238, 2004.
9. Dandona P, Chaudhuri A, Aljada A. Endothelial dysfunction and hypertension in diabetes mellitus. Med Clin North Am 88:911-931, 2004.
10. Kefalides NA. Basement membrane research in diabetes mellitus. Coll Relat Res 1:295-299, 1981.
11. Colwell JA, Lopes-Virella MF. A review of the development of large-vessel disease in diabetes mellitus. Am J Med 85:113-118, 1988.
12. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 4:224-238, 2002.
13. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 60:443-475, 1991.
14. Kanwar YS, Linker A, Farquhar MG. Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion. J Cell Biol 86:688-693, 1980.
15. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32:219-226, 1989.
16. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36:374-381, 1987.
17. Parthasarathy N, Spiro RG. Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes 31:738-741, 1982.
18. Hardebo JE, Kahrstrom J. Endothelial negative surface charge areas and blood-brain barrier function. Acta Physiol Scand 125:495-499, 1985.
19. Vlodavsky I, Goldshmidt O, Zcharia E, Metzger S, Chajek-Shaul T, Atzmon R, Guatta-Rangini Z, Friedmann Y. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie 83:831-839, 2001.
20. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112-127, 1992.
21. Katz A, Van Dijk DJ, Aingorn H, Erman A, Davies M, Darmon D, Hurvitz H, Vlodavsky I. Involvement of human heparanase in the pathogenesis of diabetic nephropathy. Isr Med Assoc J 4:996-1002, 2002.
22. Maxhimer JB, Somenek M, Rao G, Pesce CE, Baldwin D, Jr., Gattuso P, Schwartz MM, Lewis EJ, Prinz RA, Xu X. Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54:2172-2178, 2005.
23. Han J, Mandal AK, Hiebert LM. Endothelial cell injury by high glucose and heparanase is prevented by insulin, heparin and basic fibroblast growth factor. Cardiovasc Diabetol 4:1-12, 2005.
24. Hiebert LM, Liu JM. Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 83:47-51, 1990.
25. Mandal AK, Puchalski JT, Lemley-Gillespie S, Taylor CA, Kohno M. Effect of insulin and heparin on glucose-induced vascular damage in cell culture. Kidney Int 57:2492-2501, 2000.
26. Broadley KN, Aquino AM, Woodward SC, Buckley-Sturrock A, Sato Y, Rifkin DB, Davidson JM. Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest 61:571-575, 1989.
27. Gotlieb AI, Spector W. Migration into an in vitro experimental wound: a comparison of porcine aortic endothelial and smooth muscle cells and the effect of culture irradiation. Am J Pathol 103:271-282, 1981.
28. Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z, Vlodavsky I. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 76:1306-1313, 1985.
29. Muir H. Structure and function of proteoglycans of cartilage and cell-matrix interactions. Soc Gen Physiol Ser 32:87-99, 1977.
30. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777, 1999.
31. Kraemer PM. Heparan sulfates of cultured cells. II. Acid-soluble and -precipitable species of different cell lines. Biochemistry 10:1445-1451, 1971.
32. Kolset SO, Salmivirta M. Cell surface heparan sulfate proteoglycans and lipoprotein metabolism. Cell Mol Life Sci 56:857-870, 1999.
33. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156-167, 1998.
34. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5:793-802, 1999.
35. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5:803-809, 1999.
36. Godder K, Vlodavsky I, Eldor A, Weksler BB, Haimovitz-Freidman A, Fuks Z. Heparanase activity in cultured endothelial cells. J Cell Physiol 148:274-280, 1991.
37. Nakajima M, Irimura T, Nicolson GL. A solid-phase substrate of heparanase: its application to assay of human melanoma for heparan sulfate degradative activity. Anal Biochem 157:162-171, 1986.
38. Moscatelli DA, Presta M, Mignatti P, Mullins DE, Crowe RM, Rifkin DB. Purification and biological activities of an angiogenesis factor from human placenta. Anticancer Res 6:861-863, 1986.
39. Mandal AK, Ping T, Han J, Hiebert LM. Protective effects of insulin and heparin on basic fibroblast growth factor in high glucose treated cultured endothelial cells (abstract). J Am Soc Nephrol 340A, 2002.
40. Yokoyama H, Sato K, Okudaira M, Morita C, Takahashi C, Suzuki D, Sakai H, Iwamoto Y. Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Kidney Int 56:650-658, 1999.
41. Perez-Blanco FJ, Arrabal-Martin M, Villen I, Zuluaga A, Rodriguez-Cuartero A. Urinary activity of N-acetyl-beta-glucosaminidase in patients with nephrolithiasis. Nephron 86:518-519, 2000.
42. Tamsma JT, van den BJ, Bruijn JA, Assmann KJ, Weening JJ, Berden JH, Wieslander J, Schrama E, Hermans J, Veerkamp JH. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37:313-320, 1994.
43. Rosenzweig LJ, Kanwar YS. Removal of sulfated (heparan sulfate) or nonsulfated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin. Lab Invest 47:177-184, 1982.
44. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, Goldschmeding R, Zcharia E, Vlodavsky I, van der Vlag, Berden JH. Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70:2100-2108, 2006.
45. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 36:316-322, 1993.
46. Richardson JV, Wright CB, Hiratzka LF. The role of endothelium in the patency of small venous substitutes. J Surg Res 28:556-562, 1980.
47. Fairman RP, Sessler CN, Bierman M, Glauser FL. Protamine sulfate causes pulmonary hypertension and edema in isolated rat lungs. J Appl Physiol 62:1363-1367, 1987.
48. Peterson MW, Stone P, Shasby DM. Cationic neutrophil proteins increase transendothelial albumin movement. J Appl Physiol 62:1521-1530, 1987.
49. Hiebert LM, Wice SM, McDuffie NM, Jaques LB. The heparin target organ - the endothelium. Studies in a rat model. Q J Med 86:341-348, 1993.
50. Nader HB, Toma L, Pinhal MA, Buonassisi V, Colburn P, Dietrich CP. Effect of heparin and dextran sulfate on the synthesis and structure of heparan sulfate from cultured endothelial cells. Semin Thromb Hemost 17(Suppl 1):47-56, 1991.
51. Mandal AK, Ping T, Caldwell SJ, Bagnell R, Hiebert LM. Electron microscopic analysis of glucose-induced endothelial damage in primary culture: possible mechanism and prevention. Histol Histopathol 21:941-950, 2006.
52. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 70:551-557, 1987.
53. Folkman J, Klagsbrun M. Angiogenic factors. Science 235:442-447, 1987.